Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Downgrades Kaman to Sector Weight

Keybanc Downgrades Kaman to Sector Weight

Keybanc analyst Steve Barger downgrades Kaman (NYSE:KAMN) from Overweight to Sector Weight.

byBenzinga Newsdesk

November 2, 2022

1 minute read

Keybanc analyst Steve Barger downgrades Kaman (NYSE:KAMN) from Overweight to Sector Weight.

Barron’s Weekend Stock Picks: IBM, Twilio And The Rise Of Electrification

By Justin Chan

June 3, 6:18 PM

Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read.

CHPT

Why Cormedix (CRMD) Stock Is Getting Hammered

By Henry Khederian

Today, 9:22 AM

CorMedix Inc. (NASDAQ: CRMD) shares are trading lower by 23.27% to $3.89 Thursday morning after the company priced its public offering of 7.5 million shares at $4 per share and pre-funded warrants to purchase up to 2.5 million shares at

CRMD

News

What’s Going On With Verizon (VZ) Stock?

By Henry Khederian

October 23, 10:29 AM

Verizon Communications Inc. (NYSE: VZ) shares are trading marginally lower by 0.4% to $31.44 Monday morning ahead of the company's Tuesday earnings report. Analysts estimate that Veriz

Sustained Patient Response To KRYSTEXXA Injection With Methotrexate Compared To KRYSTEXXA Alone Shown Through Month 12 In MIRROR Randomized Controlled Trial

By Benzinga Newsdesk

November 8, 11:01 AM

-- Month 12 results from MIRROR randomized controlled trial to be featured on Nov. 13, 11:45 a.m. EST during plenary session at the American College of Rheumatology Convergence 2022 -- -- Imaging analyses visualize

HZNP

Keybanc Downgrades Kaman to Sector Weight

Related Posts

Barron’s Weekend Stock Picks: IBM, Twilio And The Rise Of Electrification

Why Cormedix (CRMD) Stock Is Getting Hammered

What’s Going On With Verizon (VZ) Stock?

Sustained Patient Response To KRYSTEXXA Injection With Methotrexate Compared To KRYSTEXXA Alone Shown Through Month 12 In MIRROR Randomized Controlled Trial